Skip to content
Themes / Medical Devices & Diagnostics

Medical Devices & Diagnostics

Diagnostic chains, medical equipment, consumables, devices, and laboratory products.

Medical Devices & DiagnosticsAuto-built
Theme price path

Medical Devices & Diagnostics vs Nifty 500

Weekly basket performance over the latest 52 observations. Green is ahead of Nifty 500; red is behind.

Through 09 Oct 2026
Coverage healthy
Theme aheadTheme behindNifty 500Base 100 at the first visible weekLatest: Outperforming +4.9%
82889410110717 Oct 2025 | Medical Devices & Diagnostics 100.0 | Nifty 500 100.0 | In line 0.0% | breadth 56% | coverage 94%24 Oct 2025 | Medical Devices & Diagnostics 100.2 | Nifty 500 100.4 | Underperforming -0.2% | breadth 44% | coverage 94%31 Oct 2025 | Medical Devices & Diagnostics 104.4 | Nifty 500 100.5 | Outperforming +3.9% | breadth 69% | coverage 94%07 Nov 2025 | Medical Devices & Diagnostics 104.9 | Nifty 500 99.7 | Outperforming +5.2% | breadth 50% | coverage 94%14 Nov 2025 | Medical Devices & Diagnostics 104.1 | Nifty 500 101.0 | Outperforming +3.1% | breadth 50% | coverage 94%21 Nov 2025 | Medical Devices & Diagnostics 101.7 | Nifty 500 100.8 | Outperforming +0.9% | breadth 25% | coverage 94%28 Nov 2025 | Medical Devices & Diagnostics 103.5 | Nifty 500 101.4 | Outperforming +2.1% | breadth 50% | coverage 94%05 Dec 2025 | Medical Devices & Diagnostics 100.9 | Nifty 500 101.0 | Underperforming -0.1% | breadth 31% | coverage 94%12 Dec 2025 | Medical Devices & Diagnostics 99.9 | Nifty 500 100.5 | Underperforming -0.6% | breadth 31% | coverage 94%19 Dec 2025 | Medical Devices & Diagnostics 97.5 | Nifty 500 100.3 | Underperforming -2.8% | breadth 29% | coverage 100%26 Dec 2025 | Medical Devices & Diagnostics 98.9 | Nifty 500 100.8 | Underperforming -1.9% | breadth 65% | coverage 100%02 Jan 2026 | Medical Devices & Diagnostics 99.9 | Nifty 500 102.1 | Underperforming -2.2% | breadth 71% | coverage 100%09 Jan 2026 | Medical Devices & Diagnostics 96.8 | Nifty 500 99.4 | Underperforming -2.6% | breadth 18% | coverage 100%16 Jan 2026 | Medical Devices & Diagnostics 94.8 | Nifty 500 99.5 | Underperforming -4.7% | breadth 29% | coverage 100%23 Jan 2026 | Medical Devices & Diagnostics 90.7 | Nifty 500 96.2 | Underperforming -5.7% | breadth 19% | coverage 94%01 Feb 2026 | Medical Devices & Diagnostics 90.7 | Nifty 500 95.8 | Underperforming -5.3% | breadth 44% | coverage 94%06 Feb 2026 | Medical Devices & Diagnostics 95.0 | Nifty 500 99.3 | Underperforming -4.3% | breadth 69% | coverage 94%13 Feb 2026 | Medical Devices & Diagnostics 92.8 | Nifty 500 98.8 | Underperforming -6.1% | breadth 31% | coverage 94%20 Feb 2026 | Medical Devices & Diagnostics 90.9 | Nifty 500 99.1 | Underperforming -8.3% | breadth 24% | coverage 100%27 Feb 2026 | Medical Devices & Diagnostics 89.9 | Nifty 500 98.2 | Underperforming -8.5% | breadth 35% | coverage 100%06 Mar 2026 | Medical Devices & Diagnostics 88.0 | Nifty 500 95.3 | Underperforming -7.7% | breadth 24% | coverage 100%13 Mar 2026 | Medical Devices & Diagnostics 85.3 | Nifty 500 90.6 | Underperforming -5.8% | breadth 29% | coverage 100%20 Mar 2026 | Medical Devices & Diagnostics 86.2 | Nifty 500 90.4 | Underperforming -4.6% | breadth 47% | coverage 100%27 Mar 2026 | Medical Devices & Diagnostics 83.9 | Nifty 500 89.1 | Underperforming -5.8% | breadth 35% | coverage 100%02 Apr 2026 | Medical Devices & Diagnostics 86.4 | Nifty 500 88.7 | Underperforming -2.6% | breadth 77% | coverage 100%10 Apr 2026 | Medical Devices & Diagnostics 93.3 | Nifty 500 94.7 | Underperforming -1.5% | breadth 94% | coverage 100%17 Apr 2026 | Medical Devices & Diagnostics 95.7 | Nifty 500 96.9 | Underperforming -1.2% | breadth 77% | coverage 100%24 Apr 2026 | Medical Devices & Diagnostics 95.0 | Nifty 500 95.6 | Underperforming -0.6% | breadth 41% | coverage 100%30 Apr 2026 | Medical Devices & Diagnostics 96.9 | Nifty 500 96.1 | Outperforming +0.8% | breadth 65% | coverage 100%08 May 2026 | Medical Devices & Diagnostics 102.6 | Nifty 500 98.0 | Outperforming +4.7% | breadth 71% | coverage 100%15 May 2026 | Medical Devices & Diagnostics 99.8 | Nifty 500 95.5 | Outperforming +4.5% | breadth 18% | coverage 100%22 May 2026 | Medical Devices & Diagnostics 98.8 | Nifty 500 96.0 | Outperforming +2.9% | breadth 47% | coverage 100%29 May 2026 | Medical Devices & Diagnostics 98.6 | Nifty 500 96.0 | Outperforming +2.7% | breadth 47% | coverage 100%05 Jun 2026 | Medical Devices & Diagnostics 97.1 | Nifty 500 95.2 | Outperforming +2.0% | breadth 41% | coverage 100%12 Jun 2026 | Medical Devices & Diagnostics 95.8 | Nifty 500 95.8 | In line 0.0% | breadth 29% | coverage 100%19 Jun 2026 | Medical Devices & Diagnostics 97.9 | Nifty 500 98.2 | Underperforming -0.3% | breadth 71% | coverage 100%26 Jun 2026 | Medical Devices & Diagnostics 98.3 | Nifty 500 97.9 | Outperforming +0.4% | breadth 65% | coverage 100%03 Jul 2026 | Medical Devices & Diagnostics 100.8 | Nifty 500 98.7 | Outperforming +2.1% | breadth 77% | coverage 100%10 Jul 2026 | Medical Devices & Diagnostics 100.2 | Nifty 500 99.0 | Outperforming +1.2% | breadth 47% | coverage 100%17 Jul 2026 | Medical Devices & Diagnostics 97.7 | Nifty 500 98.9 | Underperforming -1.2% | breadth 29% | coverage 100%24 Jul 2026 | Medical Devices & Diagnostics 98.3 | Nifty 500 97.2 | Outperforming +1.1% | breadth 47% | coverage 100%31 Jul 2026 | Medical Devices & Diagnostics 100.0 | Nifty 500 99.4 | Outperforming +0.6% | breadth 65% | coverage 100%07 Aug 2026 | Medical Devices & Diagnostics 100.5 | Nifty 500 100.5 | In line 0.0% | breadth 41% | coverage 100%14 Aug 2026 | Medical Devices & Diagnostics 104.2 | Nifty 500 100.0 | Outperforming +4.2% | breadth 65% | coverage 100%21 Aug 2026 | Medical Devices & Diagnostics 101.7 | Nifty 500 99.6 | Outperforming +2.1% | breadth 35% | coverage 100%28 Aug 2026 | Medical Devices & Diagnostics 102.7 | Nifty 500 99.7 | Outperforming +3.0% | breadth 71% | coverage 100%04 Sept 2026 | Medical Devices & Diagnostics 102.9 | Nifty 500 98.5 | Outperforming +4.5% | breadth 47% | coverage 100%11 Sept 2026 | Medical Devices & Diagnostics 101.5 | Nifty 500 96.9 | Outperforming +4.7% | breadth 35% | coverage 100%18 Sept 2026 | Medical Devices & Diagnostics 101.6 | Nifty 500 96.8 | Outperforming +5.0% | breadth 47% | coverage 100%25 Sept 2026 | Medical Devices & Diagnostics 103.1 | Nifty 500 95.8 | Outperforming +7.6% | breadth 65% | coverage 100%01 Oct 2026 | Medical Devices & Diagnostics 100.3 | Nifty 500 92.6 | Outperforming +8.3% | breadth 29% | coverage 100%09 Oct 2026 | Medical Devices & Diagnostics 97.2 | Nifty 500 92.7 | Outperforming +4.9% | breadth 18% | coverage 100%Outperforming +4.9%17 Oct 202510 Apr 202609 Oct 2026
Theme return
-2.8%
Nifty 500
-7.3%
Vs Nifty 500
+4.9%
Latest coverage
17/17
How this plot is calculated

The theme line is green when its cumulative rebased performance is above Nifty 500 and red when it is below. The chart callout shows the latest relative performance as the theme level divided by the benchmark level, minus one.

The basket uses the theme's current reviewed companies. For each available week, we calculate every valid constituent's close-to-close return and give each company the same weight. If a weekly rollup is missing or lags the daily series, the final available daily close in that week is used.

For baskets with at least 10 valid stocks, the highest and lowest 5% of weekly returns are trimmed to reduce split, corporate-action, and single-stock distortions. Weekly basket returns are then compounded and rebased to 100 beside the Nifty 500.

Breadth is the share of valid constituents that rose that week. Coverage is the number with usable aligned prices divided by current membership. Weekly moves above 80% are excluded as likely data or corporate-action outliers.

Limitation: this is a current-membership historical reconstruction, not a point-in-time investable index. It can contain survivorship bias and excludes costs, liquidity impact, dividends, and rebalancing turnover.

Model note: Current-member weekly equal-weight returns (5% tails trimmed for baskets of 10+), compounded and rebased to 100 against Nifty 500; lagging weekly rollups are patched with the final available daily close, and rotation uses 13-week excess return with four-week acceleration.

Theme scorecard

Measures whether this idea is investable today by blending cohort quality, valuation cushion, and price momentum. It is a research filter, not advice.

Build portfolio from this theme
Theme
27
Stretched
Quality
19
Valuation
22
Momentum
51
Positive MoS
24%
P/E 51.1 · ROCE 18%
Curated research view

Medical Devices & Diagnostics

A focused investor view: high-conviction names first, then small/micro exposure only as controlled satellite risk. Live U-Score and MoS still come from the current database.

67/100
Theme score
Moderate-High
Investability
41.1
Live avg U
-1050.4%
Live avg MoS

Curated company map

Names from the curated theme note. Solid chips are present in the live eligible cohort; dashed chips need membership review, ticker verification, or may be indirect/unlisted exposure.

8/8 live eligible

Investment thesis

Import substitution, hospital capacity, preventive testing, chronic-disease monitoring, and domestic device manufacturing support scalable diagnostics and medical-product companies.

1-2 year outlook: Constructive for branded diagnostic networks and compliant device manufacturers with export optionality.
Recommended allocation: 4-7%.

Key triggers

  • Testing-volume growth
  • Device localisation
  • Hospital and laboratory capex
  • Export approvals

Major risks

  • Price regulation
  • Procurement concentration
  • Quality failures
  • High receivables
Small, micro, and SME names should be opt-in exposure. Suggested filters: U-Score above 65, positive MoS, Piotroski 7+, debt/equity below 0.8, promoter pledge below 10%, and enough traded value to exit without slippage.

Thesis

A direct healthcare-products and diagnostics cohort. Hospitals and conventional drug manufacturers are excluded unless they operate a separately identifiable diagnostics or medical-device business.

  • ▸Domestic device manufacturing and import substitution
  • ▸Preventive testing and diagnostics penetration
  • ▸Regulatory quality and procurement risk

Top picks · ranked by U-Score within this cohort

Full cohort

OSELDEVICESME
Osel Devices Ltd.
Pharma
FAIR VALUE

Direct diagnostics, medical-device, medical-equipment, consumables, or laboratory-product operations.

MoS: +50.7%Piotroski: 6/9ROCE: 23%P/E: 22.3D/E: 0.46
58
U-Score
₹366.35
Open →
THYROCAREMicro
Thyrocare Technologies Limited
Pharma
FAIR VALUE

Direct diagnostics, medical-device, medical-equipment, consumables, or laboratory-product operations.

MoS: -130.7%Piotroski: 8/9ROCE: 35%P/E: 47.7D/E: 0.09
53
U-Score
₹499.70
Open →
SURAKSHASmall
Suraksha Diagnostic Limited
Pharma
FAIR VALUE

Direct diagnostics, medical-device, medical-equipment, consumables, or laboratory-product operations.

MoS: -2.2%Piotroski: 8/9ROCE: 17%P/E: 48.3D/E: 0.53
50
U-Score
₹316.25
Open →
LALPATHLABSmall
Dr. Lal Path Labs Ltd.
Pharma
FAIR VALUE

Direct diagnostics, medical-device, medical-equipment, consumables, or laboratory-product operations.

MoS: -32.9%Piotroski: 8/9ROCE: 28%P/E: 58.8D/E: 0.08
48
U-Score
₹1933.60
Open →
VIJAYALarge
Vijaya Diagnostic Centre Limited
Pharma
WATCHLIST

Direct diagnostics, medical-device, medical-equipment, consumables, or laboratory-product operations.

MoS: -75.1%Piotroski: 8/9ROCE: 21%P/E: 78.1D/E: 0.44
43
U-Score
₹1436.60
Open →
METROPOLISMicro
Metropolis Healthcare Limited
Pharma
WATCHLIST

Direct diagnostics, medical-device, medical-equipment, consumables, or laboratory-product operations.

MoS: -574.8%Piotroski: 8/9ROCE: 18%P/E: 55.2D/E: 0.15
39
U-Score
₹529.25
Open →
NIDANSME
Nidan Laboratories And Healthcare Ltd.
Pharma
WATCHLIST

Direct diagnostics, medical-device, medical-equipment, consumables, or laboratory-product operations.

MoS: -137.0%Piotroski: 6/9ROCE: 6%P/E: 9.8D/E: 0.16
36
U-Score
₹13.25
Open →
POLYMEDLarge
Poly Medicure Limited
Pharma
WATCHLIST

Direct diagnostics, medical-device, medical-equipment, consumables, or laboratory-product operations.

MoS: -13.4%Piotroski: 8/9ROCE: 13%P/E: 51.3D/E: 0.11
32
U-Score
₹1587.10
Open →
VILINBIOSME
VILIN BIO MED LTD.
Pharma
OVERVALUED

Direct diagnostics, medical-device, medical-equipment, consumables, or laboratory-product operations.

MoS: +9.0%Piotroski: 7/9ROCE: 11%P/E: 44.6D/E: 0.01
31
U-Score
₹52.00
Open →
FISCHERSmall
Fischer Medical Ventures Limited
Pharma
OVERVALUED

Direct diagnostics, medical-device, medical-equipment, consumables, or laboratory-product operations.

MoS: -77.6%Piotroski: 6/9ROCE: 11%P/E: 93.6D/E: 0.28
30
U-Score
₹30.37
Open →
KRSNAASmall
Krsnaa Diagnostics Limited
Pharma
OVERVALUED

Direct diagnostics, medical-device, medical-equipment, consumables, or laboratory-product operations.

MoS: -293.6%Piotroski: 8/9ROCE: 13%P/E: 18.6D/E: 0.54
30
U-Score
₹535.50
Open →
NURECASmall
Nureca Limited
Pharma
OVERVALUED

Direct diagnostics, medical-device, medical-equipment, consumables, or laboratory-product operations.

MoS: -8220.9%Piotroski: 7/9ROCE: 3%P/E: 74.5D/E: 0.01
22
U-Score
₹331.65
Open →
TARSONSSmall
Tarsons Products Limited
Industrials
OVERVALUED

Direct diagnostics, medical-device, medical-equipment, consumables, or laboratory-product operations.

MoS: -8111.8%Piotroski: 7/9ROCE: 5%P/E: 151.0D/E: 0.62
21
U-Score
₹320.95
Open →
INFLUXSME
Influx Healthtech Ltd.
Pharma
OVERVALUED

Direct diagnostics, medical-device, medical-equipment, consumables, or laboratory-product operations.

MoS: -312.4%Piotroski: 5/9P/E: 29.9D/E: 0.00
15
U-Score
₹270.35
Open →
The rationale above is editorial — the ranking uses our U-Score engine so the names you see first are the strongest fundamentals fit, not the most popular or most-mentioned. Re-rank yourself if you weigh valuation or quality differently. All information is for study purposes only — consult your financial advisor before investing.